期刊文献+

TNBC原发灶与腋淋巴结转移灶中ER、PR、Her-2的表达变化与预后的相关性 被引量:4

A study on the ER, PR and Her -2 expression statuses between primary lesion and metastatic axillary lymph nodes of TNBC
暂未订购
导出
摘要 目的探讨雌激素受体、孕激素受体、人表皮生长因子受体-2在三阴性乳腺癌原发灶和腋淋巴结转移灶中表达有无差异及其与患者预后的相关性。方法运用免疫组化法分别检测45例TN—Bc原发灶及腋淋巴结转移灶中ER、PR、Her-2的表达,用Kaplan—Meier生存曲线分析TNBC腋淋巴结转移灶中这些指标的变化与生存时间的关系。结果与TNBC原发灶相比,腋淋巴结转移灶中ER、PR、Her-2仍表达阴性的患者占48.9%,而至少有一项指标表达阳性的患者占51.1%,即与原发灶表达不一致,差异具有统计学意义,且这种表达差异与生存时间存在相关性(P=0.013)。腋淋巴结转移灶免疫组化表达与原发灶一致组的生存时间要短于不一致组(P=0.010),用LogRank法检验具有统计学意义(P=0.048)。结论ER、PR、Her-2在TNBC原发灶和腋淋巴结转移灶中的表达存在不一致现象,且这种不一致现象与生存时间具有相关性。 Objective To investigate the difference of expressions of ER, PR and Her 2 status between primary lesion and metastatic axillary lymph nodes of TNBC, and the relationship between the variability and prog nosis of patients. Methods The expressions of ER, PR and Her 2 were detected in primary lesion and metastat ic axillary lymph nodes in 45 cases of TNBC by immunohistochemistry, and then analyzed the relationship between modifications of these markers and live time by Kaplan Meier survival curves. Results Compared with the pri mary lesion of TNBC ,48.9% patients'axillary lymph node metastases of ER, PR and Her 2 still expressed nega tive, but 51.1% patients had at least one marker positive expression, means immunohistochemical staining of axil lary lymph nodes were different to primary lesion ,with a significant difference between them. The expression varia bility was significant correlated with live time( P = 0. 013 ). The live time of the group which immunohistochemical staining of axillary lymph nodes similar to the primary lesion of TNBC was shorter than the group that was differ ent to primary lesion( P =0.010) ,and there had statistical significance by Log Rank method( P = 0. 048 ). Con clusion In primary lesion and metastatic axillary lymph nodes of TNBC,the expressions of ER,PR and Her 2 were difference. And the variability was correlated with life time of patients.
出处 《实用肿瘤学杂志》 CAS 2013年第1期54-59,共6页 Practical Oncology Journal
基金 黑龙江省自然科学基金项目(D201103)
关键词 三阴性乳腺癌 淋巴结转移 预后 Triple negative breast cancer(TNBC) Lymph nodes metastasis Prognosis
  • 相关文献

参考文献14

  • 1刘颖(综述),赵长宏(审校),蔡莉(审校).三阴性乳腺癌的研究进展[J].实用肿瘤学杂志,2010,24(4):320-323. 被引量:2
  • 2Adamo V, Ricciardi GR, De Placido S, et al. Management and treatment of triple - negative breast cancer patients from the NEMESI study:an Italian experience [ J ]. Eur J Canc- er,2012,48(5) :642 -647.
  • 3Gluz O, Liedtke C, Gottschalk N, et al. Triple - negative breast cancer- current status and future directions [ J ]. Ann 0ncol,2009,20(12) :1913 - 1927.
  • 4Standacher L, Cottu PH, Dieras V, et al. Platinum - based chemotherapy in metastatic triple - negative breast cancer: the Institut Curie experience [ J ]. Ann Oncol, 2011,22 (4) :848 - 856.
  • 5Fomier M, Fumoleau P. The paradox of triple negative breast cancer: novel approaches to treatment [ J ]. Breast J,2012, 18(1) :41 -51.
  • 6De Laurentiis M, Cianniello D, Caputo R, et al. Treatment of triple negative breast cancer ( TNBC ) : current options and future perspectives [ J ]. Cancer Treatment Reviews, 2010, 36 ( Suppl 3 ) : $80 - $86.
  • 7曹华,闫茂生,郑涛,许瑞莲,陈亦欣,王树滨,刘雅洁.132例三阴性乳腺癌患者的临床特征与预后分析[J].实用肿瘤学杂志,2009,23(2):101-105. 被引量:8
  • 8Hernandez - Aya LF, Chavez - Macgregor M, Lei X, et al. Nodal status and clinical outcomes in a large cohort of pa- tients with triple - negative breast cancer [ J ]. J Clin Oncol, 2011,29 (19) :2628 - 2634.
  • 9Lower EE, Glass EL, Bradley DA, et al. Impact of metastatic estrogen receptor and progesterone receptor status on surviv- al [J]. Breast Cancer Res Treat,2005,90( 1 ) :65 -70.
  • 10Lower EE, Glass E, Blau R, et al. Her - 2/neu expression in primary and metastatic breast cancer [ J ]. Breast CancerRes Treat,2009,113 (2) : 301 - 306.

二级参考文献42

  • 1Raha EA, Elsayed ME, Green AR, et al. Prognostic markers in triple - negative breast cancer [ J]. Cancer, 2007, 109 (1) :25 -32.
  • 2Morris GJ,Naidu S,Topham AK,et al. Differences in breast carcinoma characteristics in newly diagnosed African - American and Caucasian patients : A single - institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database [ J ]. Cancer,2007,110(4) :876 - 884.
  • 3Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets [ J]. PNAS ,2003,100:8418 - 8423.
  • 4Reis - Filho JS, Tutt AN. Triple negative breast cancer: a critical review [ J ]. Histopathology, 2008,52 ( 1 ) : 108 - 118.
  • 5Kim M J, Ro JY, Ahn SH, et al. Clinicopathologicsignificance of the basal - like subtype of breast cancer: A comparison with hormone receptor and Her- 2/neu- overexpressing phenotypes [ J ]. Hum Pathol,2006,37 (9) : 1217 - 1226.
  • 6Sara M, Bando Y, Takahashi N, et al. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple - negative breast cancer [ J ]. J Surg Oncol,2008,97( 1 ) :30 -34.
  • 7Dent R, Trudeau M, Pritchard KJ, et al. Triple negative breast cancer: clinical features and patterns of recurrence [ J]. Clin Cancer Res ,2007,13:4429 - 4434.
  • 8Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes ,and survival in the Carolina Breast Cancer Study [ J]. JAMA ,2006 ,295 (21) :24922 - 24502.
  • 9Tischkowitz M, Brunet JS, Begin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer[J]. BMC Cancer,2007,7 : 134.
  • 10Carey LA,Dees EC,Sawyer L, et al. The triple negative paradox:primary tumor chemosensitivity of breast cancer subtypes[ J]. Clin Cancer Res, 2007, 13 (8) : 2329 - 2334.

共引文献8

同被引文献47

引证文献4

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部